Project Grant R01HL172898
Award Date 8/15/25
Completion Date 5/31/29
Dollars Obligated $520K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $611,014 to the University of Connecticut Health Center to develop and optimize adeno-associated virus (AAV) therapies for treating cardiac disorders caused by pathogenic variants in the TNNT2 gene. The project aims to engineer next-generation AAVs capable of delivering wild-type TNNT2 and selectively suppressing mutant TNNT2 mRNA in cardiomyocytes. This...
- This $556,295 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to advance scientific understanding of cardiac pacemaking and sinus node dysfunction (SND) through research on "conditional pacemaker cells" within distinct specialized pacemaker cell subpopulations. The project will leverage advanced optical mapping technology to directly visualize pacemaking activities within these specialized cell...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a $560,000 research initiative led by Baylor College of Medicine to develop a "triple gene therapy" treatment for ischemic heart failure. The goal is to leverage a combination of three experimental approaches - inducing cardiomyocyte proliferation, direct cardiac reprogramming of fibroblasts, and increasing angiogenesis - to synergistically regenerate...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $704,635 to the University of Florida to develop optimized adeno-associated virus (AAV) vectors for gene therapy of hemophilia. Specifically, the award aims to engineer both capsid- and genome-modified AAV3 vectors that can transduce human hepatocytes more efficiently than current AAV5 vectors, potentially reducing the required vector dose and...
- This federal Project Grant award, totaling $249,000.00, was provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The University of Texas Southwestern Medical Center in Dallas, TX. The grant supports research to better understand the molecular determinants of atrial fibrillation (AF), a common and serious heart rhythm disorder. The research aims to investigate how the transcription factor TBX5 and the chromatin remodeling protein CHD4...
- This $802,762 federal Project Grant was awarded on February 1, 2025 by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The University of Texas Southwestern Medical Center in Dallas, TX. The grant supports research to interpret the impact of genetic variants, both coding and non-coding, on the development of congenital heart disease (CHD) by defining cardiac gene regulatory networks. The research aims to characterize the functions of variants in...
- This $125,703 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research investigating the role of the SYNE1-giant gene in atrial cardiomyopathy. The principal investigator is conducting a comprehensive study to understand the mechanisms by which mutations in the SYNE1 gene, which encodes mechanosensitive proteins in the nuclear envelope, contribute to the development of atrial fibrillation and sinus node dysfunction....
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop and validate nanotherapies to address three key issues in the treatment of chronic Chagas disease. The $666,319 award to the University of Virginia supports research to: 1) Treat chronic Chagas cardiomyopathy without impacting parasitemia or parasite reservoirs, 2) Eliminate parasite reservoirs in adipose tissue, and 3) Improve drug delivery and efficacy of...
- The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $111,699 to the University of Utah to elucidate the role of early immune cell infiltration in the development of arrhythmogenic cardiomyopathy (ACM), a devastating inherited heart disease. The key research objectives are to: 1) test whether increased neonatal immune cell recruitment accelerates arrhythmias, scar formation, and death in a mouse model of ACM; 2)...